Hemophilia B Clinical Trial
— ECLIPSEOfficial title:
Screening/Observational Protocol to Determine Patient Eligibility for Inclusion in AAV Gene Therapy Clinical Trials (ECLIPSE)
NCT number | NCT04272554 |
Other study ID # | FLT-01 |
Secondary ID | |
Status | Completed |
Phase | |
First received | |
Last updated | |
Start date | February 14, 2020 |
Est. completion date | October 10, 2022 |
Verified date | November 2022 |
Source | Freeline Therapeutics |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational [Patient Registry] |
Freeline is developing adeno-associated virus (AAV) vector based gene therapies for a number of diseases and is actively advancing a programme in Haemophilia B (HB). This study aims to collect prospective data to characterise bleeding events and Factor IX (FIX) concentrate consumption in HB patients that can be used as baseline for participants who elect to participate in a subsequent Freeline gene therapy study. The study will also screen participants for antibodies to a novel AAV vector to assess their suitability for inclusion in a Freeline gene therapy treatment study.
Status | Completed |
Enrollment | 37 |
Est. completion date | October 10, 2022 |
Est. primary completion date | October 10, 2022 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 16 Years and older |
Eligibility | Inclusion Criteria 1. Male participants, = 16 years of age. 2. Able to give full informed consent or obtain full informed consent/assent (according to local regulations) and/or obtain full informed consent from the participant's legally acceptable representative (as appropriate), and able to understand and comply with all requirements of the study, including diary completion. 3. Interested in participation in future gene therapy clinical studies. 4. Subjects with Haemophilia B with known severe or moderately severe FIX deficiency (=2% of normal circulating FIX activity) for which the subject is either on 1. Continuous routine FIX prophylaxis, OR 2. On demand FIX treatment 5. If receiving prophylaxis, participant has been on stable and adequate prophylaxis for at least 2 months prior to enrolment. Exclusion Criteria: 1. Documented evidence of liver fibrosis and/ or liver dysfunction 2. Prior treatment with a gene transfer medicinal product. 3. Known presence or history of neutralising anti-human FIX antibodies (inhibitors) 4. Previously established serological evidence of HIV-1 5. Documented active hepatitis B or C, and HBsAg or HCV RNA viral load positivity, respectively, or currently on antiviral therapy for hepatitis B or C 6. Participants at high risk of thromboembolic events (history of arterial or venous thromboembolism 7. Known coagulation disorder other than Haemophilia B 8. Known history of an allergic reaction or anaphylaxis to Factor IX products or known uncontrolled allergic conditions 9. Known history of allergy to corticosteroids or to tacrolimus or any other macrolide 10. Known medical condition that would require chronic administration of corticosteroids (excluding topical formulations) 11. History of alcohol or drug dependence. 12. Planned surgical procedure within the next 12 months requiring prophylactic FIX treatment. 13. Known active severe infection (including documented COVID-19 infection), or any other significant concurrent, uncontrolled medical condition evaluated by the investigator to interfere with adherence to the protocol procedures or with tolerance to gene therapy in a future treatment study including, but not limited to, renal, hepatic, cardiovascular, opthalmological, hematological, immunological, gastrointestinal, endocrine, pulmonary, neurological, cerebral or psychiatric disease, malignancy or any other psychological disorder. |
Country | Name | City | State |
---|---|---|---|
Australia | Royal Children's Hospital, Parkville | Melbourne | |
Australia | The Alfred Hospital | Melbourne | |
Australia | Calvary Mater Hospital | Newcastle | |
Australia | Royal Prince Alfred Hospital | Sydney | |
Australia | Westmead Hospital | Sydney | |
Austria | Medical University of Vienna | Vienna | |
Canada | McMaster University Medical Centre | Hamilton | |
Canada | Lawson Health Research Institute | London | |
Canada | The Moncton Hospital | Moncton | |
Canada | Saskatoon City Hospital | Saskatoon | |
Canada | University of Alberta Hospital | Winnipeg | |
France | Hôpital Louis Pradel - HCL | Bron | |
France | CHU Bicetre | Paris | |
France | Hopital Necker-Enfants Malades - AP-HP | Paris | |
Germany | Universitaetsklinikum Frankfurt - Klinikum der Johann Wolfgang Goethe Universitaet | Frankfurt | |
Germany | Universitaetsklinikum des Saarlandes und Medizinische Fakultaet der Universitaet des Saarlandes | Homburg | |
Ireland | St James Hospital | Dublin | |
Italy | Azienda Ospedaliero-Universitaria Careggi | Firenze | |
Italy | Istituto Giannina Gaslini | Genova | |
Italy | Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano | Milan | |
Italy | Citta della Salute e della Scienza di Torino - Ospedale le Molinette | Torino | |
Netherlands | Groningen UMC | Groningen | |
Netherlands | Erasmus MC | Rotterdam | |
Netherlands | Universitair Medisch Centrum Utrecht | Utrecht | |
South Africa | University of Cape Town Clinical Research Center | Cape Town | |
South Africa | Charlotte Maxeke Johannesburg Academic Hospital | Johannesburg | |
Turkey | Istanbul University Faculty of Medicine | Istanbul | |
Turkey | Ege University Medical Faculty | Izmir | |
Turkey | Samsun Ondokuz Mayis University Medical Faculty | Samsun | |
Turkey | Özel Acibadem Adana Hastanesi | Seyhan | |
United Kingdom | Queen Elizabeth Hospital | Birmingham | |
United Kingdom | The Haemophilia and Thrombosis Centre | Canterbury | Kent |
United Kingdom | Cardiff University Hospital | Cardiff | |
United Kingdom | Glasgow Royal Infirmary | Glasgow | |
United Kingdom | Hammersmith Hospital | London | |
United Kingdom | Royal Free London NHS Foundation Tust | London | |
United Kingdom | St Thomas' Hospital | London | |
United Kingdom | Manchester Royal Infirmary | Manchester | |
United Kingdom | Newcastle Hemophilia Comprehensive Care Centre | Newcastle | |
United States | University of Michigan | Ann Arbor | Michigan |
United States | Hemophilia Center of Western New York | Buffalo | New York |
United States | University of North Carolina (UNC) | Chapel Hill | North Carolina |
United States | Rush University Medical Center | Chicago | Illinois |
United States | University Hospitals Cleveland Medical Center | Cleveland | Ohio |
United States | Nationwide Childrens Hospital | Columbus | Ohio |
United States | Lombardi Comprehensive Cancer Center at Georgetown University | Georgetown | Washington |
United States | East Carolina University | Greenville | North Carolina |
United States | Indiana Hemophilia and Thrombosis Center | Indianapolis | Indiana |
United States | Children's Hospital of Los Angeles | Los Angeles | California |
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
United States | Blood Center of Wisconsin | Milwaukee | Wisconsin |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | University of Nebraska Medical Center | Omaha | Nebraska |
United States | Phoenix Childrens Hospital | Phoenix | Arizona |
United States | University of California - Davis | Sacramento | California |
United States | University of South Florida | Tampa | Florida |
Lead Sponsor | Collaborator |
---|---|
Freeline Therapeutics |
United States, Australia, Austria, Canada, France, Germany, Ireland, Italy, Netherlands, South Africa, Turkey, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Bleeding episodes | Bleeding episode data recorded during the study | 6 - 24 months | |
Primary | Factor IX replacement therapy consumption | Factor IX replacement therapy data recorded during the study | 6 - 24 months | |
Secondary | To screen Haemophilia B patients for neutralising antibodies to a novel AAV vector (AAVS3). | AAV antibody assay result | 6 - 24 months | |
Secondary | To characterise baseline clinical parameters related to Haemophilia B. | Target joint data and health reasource utilisation | 6 - 24 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04072237 -
Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia
|
Phase 1 | |
Completed |
NCT02199717 -
An Institutional Pilot Study to Investigate Physical Activity Patterns in Boys With Hemophilia
|
N/A | |
Completed |
NCT01662531 -
A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B
|
Phase 3 | |
Completed |
NCT01335061 -
Study To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia B
|
Phase 3 | |
Completed |
NCT01217255 -
Comparing the Burden of Illness of Hemophilia in the Developing and the Developed World
|
||
Completed |
NCT00037557 -
Study Evaluating rFIX; BeneFIX in Severe Hemophilia B
|
Phase 3 | |
Completed |
NCT02554773 -
An Open-label Extension Study of an Investigational Drug, Fitusiran, in Patients With Moderate or Severe Hemophilia A or B
|
Phase 1/Phase 2 | |
Terminated |
NCT02807753 -
The Hemophilia Ultrasound Project
|
||
Active, not recruiting |
NCT03901755 -
An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B
|
||
Not yet recruiting |
NCT05980377 -
Patterns of Hemophilia Care in Assiut Children Patients
|
||
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Terminated |
NCT03248141 -
Understanding Hemophilia A and B Drug Dosage Administration Patterns
|
||
Terminated |
NCT01460147 -
Osteoporosis and MRI Study in Hemophilia
|
N/A | |
Completed |
NCT03818529 -
ATHN 8: Previously Untreated Patients (PUPs) Matter Study
|
||
Completed |
NCT02571569 -
A Single Escalating Dose and Multiple Dose Study of BAY 1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors
|
Phase 1 | |
Terminated |
NCT01620801 -
Hemophilia B Gene Therapy With AAV8 Vector
|
Phase 1 | |
Completed |
NCT01233440 -
Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B
|
Phase 1 | |
Active, not recruiting |
NCT04135300 -
Gene Therapy for Chinese Hemophilia B
|
N/A | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Terminated |
NCT00947193 -
Study of Ataluren (PTC124) in Hemophilia A and B
|
Phase 2 |